RedCrow's mission is not simply to help investors discover early stage startups in the booming healthcare and medtech sectors, but to connect those entrepreneurs to the industry's top talking heads, says the company's chairman Jerry Harrison. "RedCrow does more than list the companies, we also vet them and help guide them," said Harrison. "Most crowdfunding platforms don't offer that kind of expertise." Harrison is most widely known for his work as member of the Rock and Roll Hall of Fame band the Talking Heads and as an original member of The Modern Lovers. Outside of his rock and roll credentials, Harrison has an extraordinary background as an entrepreneur as the co-founder of companies like Garageband.com, an Internet music resource and early pioneer in crowdsourcing. Harrison founded the company along with CEO Brian Smith, a former Morgan Stanley financial advisor and wealth manager. Founded in 2016, San Francisco-based RedCrow is an equity crowdfunding portal that provides investment opportunities for accredited investors. Unlike other crowdfunding portals, RedCrow enables the public to invest alongside industry experts who serve as RedCrow advisors and strategic investment partners. In 2017, RedCrow plans to open its exclusive offerings to Title III, non-accredited investors, fully embracing the crowd.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.